{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:43:25Z","timestamp":1789731805345,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T00:00:00Z","timestamp":1505088000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["PP00P3_157448"],"award-info":[{"award-number":["PP00P3_157448"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00262-017-2061-4","type":"journal-article","created":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T18:01:37Z","timestamp":1505152897000},"page":"39-45","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease"],"prefix":"10.1007","volume":"67","author":[{"given":"Stefan","family":"Diem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Hasan Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph J.","family":"Ackermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bomze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor H.","family":"Koelzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Jochum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Speiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten D.","family":"Mertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Flatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,11]]},"reference":[{"issue":"8","key":"2061_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723. doi:\n                        10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"issue":"26","key":"2061_CR2","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26):2521\u20132532. doi:\n                        10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"issue":"4","key":"2061_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375\u2013384. doi:\n                        10.1016\/S1470-2045(15)70076-8","journal-title":"Lancet Oncol"},{"issue":"4","key":"2061_CR4","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320\u2013330. doi:\n                        10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"issue":"1","key":"2061_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23\u201334. doi:\n                        10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"issue":"8","key":"2061_CR6","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16(8):908\u2013918. doi:\n                        10.1016\/S1470-2045(15)00083-2","journal-title":"Lancet Oncol"},{"issue":"7528","key":"2061_CR7","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568\u2013571. doi:\n                        10.1038\/nature13954","journal-title":"Nature"},{"key":"2061_CR8","first-page":"3","volume":"9","author":"DA Oble","year":"2009","unstructured":"Oble DA, Loewe R, Yu P et al (2009) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 9:3","journal-title":"Cancer Immun"},{"issue":"24","key":"2061_CR9","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/jnci\/81.24.1893","volume":"81","author":"WH Clark Jr","year":"1989","unstructured":"Clark WH Jr, Elder DE, Dt Guerry et al (1989) Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81(24):1893\u20131904","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"2061_CR10","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5","volume":"77","author":"CG Clemente","year":"1996","unstructured":"Clemente CG, Mihm MC Jr, Bufalino R et al (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77(7):1303\u20131310. doi:\n                        10.1002\/(SICI)1097-0142(19960401)77:7<1303:AID-CNCR12>3.0.CO;2-5","journal-title":"Cancer"},{"issue":"15","key":"2061_CR11","first-page":"3569","volume":"53","author":"A Mackensen","year":"1993","unstructured":"Mackensen A, Ferradini L, Carcelain G et al (1993) Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res 53(15):3569\u20133573","journal-title":"Cancer Res"},{"issue":"2","key":"2061_CR12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/1523-1747.ep12479662","volume":"97","author":"FJ Tefany","year":"1991","unstructured":"Tefany FJ, Barnetson RS, Halliday GM et al (1991) Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol 97(2):197\u2013202","journal-title":"J Invest Dermatol"},{"key":"2061_CR13","doi-asserted-by":"publisher","first-page":"e28498","DOI":"10.4161\/onci.28498","volume":"3","author":"M Rodolfo","year":"2014","unstructured":"Rodolfo M, Castelli C, Rivoltini L (2014) Immune response markers in sentinel nodes may predict melanoma progression. Oncoimmunology 3:e28498. doi:\n                        10.4161\/onci.28498","journal-title":"Oncoimmunology"},{"issue":"9","key":"2061_CR14","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nri1919","volume":"6","author":"AJ Cochran","year":"2006","unstructured":"Cochran AJ, Huang RR, Lee J et al (2006) Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 6(9):659\u2013670. doi:\n                        10.1038\/nri1919","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2061_CR15","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1349-7006.2007.00672.x","volume":"99","author":"H Takeuchi","year":"2008","unstructured":"Takeuchi H, Kitajima M, Kitagawa Y (2008) Sentinel lymph node as a target of molecular diagnosis of lymphatic micrometastasis and local immunoresponse to malignant cells. Cancer Sci 99(3):441\u2013450. doi:\n                        10.1111\/j.1349-7006.2007.00672.x","journal-title":"Cancer Sci"},{"key":"2061_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1479-5876-11-43","volume":"11","author":"A Mohos","year":"2013","unstructured":"Mohos A, Sebestyen T, Liszkay G et al (2013) Immune cell profile of sentinel lymph nodes in patients with malignant melanoma - FOXP3\u00a0+\u00a0cell density in cases with positive sentinel node status is associated with unfavorable clinical outcome. J Transl Med 11:43. doi:\n                        10.1186\/1479-5876-11-43","journal-title":"J Transl Med"},{"issue":"12","key":"2061_CR17","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1038\/modpathol.2015.110","volume":"28","author":"H Kakavand","year":"2015","unstructured":"Kakavand H, Vilain RE, Wilmott JS et al (2015) Tumor PD-L1 expression, immune cell correlates and PD-1\u00a0+\u00a0lymphocytes in sentinel lymph node melanoma metastases. Mod Pathol 28(12):1535\u20131544. doi:\n                        10.1038\/modpathol.2015.110","journal-title":"Mod Pathol"},{"issue":"1","key":"2061_CR18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1158\/0008-5472.CAN-13-1672","volume":"74","author":"V Vallacchi","year":"2014","unstructured":"Vallacchi V, Vergani E, Camisaschi C et al (2014) Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression. Cancer Res 74(1):130\u2013140. doi:\n                        10.1158\/0008-5472.CAN-13-1672","journal-title":"Cancer Res"},{"issue":"19","key":"2061_CR19","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ et al (2016) Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 375(19):1845\u20131855. doi:\n                        10.1056\/NEJMoa1611299","journal-title":"N Engl J Med"},{"issue":"2","key":"2061_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. doi:\n                        10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"11","key":"2061_CR21","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1016\/j.humpath.2014.07.011","volume":"45","author":"W Kempf","year":"2014","unstructured":"Kempf W, Zollinger T, Sachs M et al (2014) Granulomas are a source of interleukin-33 expression in pulmonary and extrapulmonary sarcoidosis. Hum Pathol 45(11):2202\u20132210. doi:\n                        10.1016\/j.humpath.2014.07.011","journal-title":"Hum Pathol"},{"issue":"5","key":"2061_CR22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00262-014-1528-9","volume":"63","author":"S Kelderman","year":"2014","unstructured":"Kelderman S, Heemskerk B, van Tinteren H et al (2014) Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 63(5):449\u2013458. doi:\n                        10.1007\/s00262-014-1528-9","journal-title":"Cancer Immunol Immunother"},{"issue":"18","key":"2061_CR23","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1016\/j.ejca.2015.09.007","volume":"51","author":"S Diem","year":"2015","unstructured":"Diem S, Kasenda B, Martin-Liberal J et al (2015) Prognostic score for patients with advanced melanoma treated with ipilimumab. Eur J Cancer 51(18):2785\u20132791. doi:\n                        10.1016\/j.ejca.2015.09.007","journal-title":"Eur J Cancer"},{"issue":"3","key":"2061_CR24","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/bjc.2015.467","volume":"114","author":"S Diem","year":"2016","unstructured":"Diem S, Kasenda B, Spain L et al (2016) Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer 114(3):256\u2013261. doi:\n                        10.1038\/bjc.2015.467","journal-title":"Br J Cancer"},{"issue":"6","key":"2061_CR25","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1093\/annonc\/mdt027","volume":"24","author":"J Delyon","year":"2013","unstructured":"Delyon J, Mateus C, Lefeuvre D et al (2013) Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 24(6):1697\u20131703. doi:\n                        10.1093\/annonc\/mdt027","journal-title":"Ann Oncol"},{"issue":"7","key":"2061_CR26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa1310460","volume":"370","author":"DL Morton","year":"2014","unstructured":"Morton DL, Thompson JF, Cochran AJ et al (2014) Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 370(7):599\u2013609. doi:\n                        10.1056\/NEJMoa1310460","journal-title":"N Engl J Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-017-2061-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2061-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2061-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T06:40:16Z","timestamp":1515048016000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-017-2061-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,11]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["2061"],"URL":"https:\/\/doi.org\/10.1007\/s00262-017-2061-4","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,11]]}}}